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We appreciate Dr. Kauffman’s interest1 in our paper.2 We
agree that further exploration of the relationship between
timing of hormone therapy (HT) initiation (that is in the
perimenopausal vs postmenopausal period) and kidney
function would be of great interest. We were limited in our
evaluation of the association between HT and change in
kidney function to the postmenopausal population, as only
residents of Alberta aged X65 years receive complete
insurance coverage for prescription drugs. As such, we
were only able to ascertain prescriptions filled for this
older population. We intentionally limited our study to
women with eGFRo90 ml/min per 1.73 m2 to avoid
misclassification of kidney function as the original
modification of diet in renal disease formula was derived
using a population with measured GFR o90 ml/min per
1.73 m2 (ref. 3).
As noted in our study limitations, we were restricted in
our assessment of clinical data and thus were not able to
comment on menopausal symptomatology in either the
control group or the group using HT. However, our study
was not designed to assess the appropriateness of
prescribing HT or the HT dose, but rather change in
kidney function among women who were dispensed HT.
Although Dr. Kauffman is correct in pointing out that we
could not monitor compliance with the medication, if the
women prescribed HT in our study were not actually using
this medication regularly, then is it possible the results
observed in our study are actually an underestimate of the
true effects.
Although the baseline characteristics of study subjects
differed by exposure status, our models adjusted for these
potential covariates. In addition there was no evidence of
confounding or effect modification with angiotensin-
converting enzyme inhibitor, angiotensin II receptor
blocker, or non-steroidal antinflammatory drug use, thus
these variables were not included in our final models.
Although we strongly agree with the suggestion that
randomized controlled trials are needed to test the
potential benefits or harm of HT on kidney function in
both the perimenopausal and postmenopausal woman, the
results of our study suggest that surveillance of kidney
function in the elderly woman ingesting oral estrogen is
warranted.
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To the Editor: Periyasamy-Thandavan et al.1 demonstrated
for the first time a cytoprotective role for autophagy in
cisplatin nephrotoxicity. In the accompanying commentary,
Lieberthal states that the extent to which autophagy can
ameliorate kidney injury caused by other types of renal
insults remains to be determined.
We have recently demonstrated that cyclosporine induces
autophagy, both in vitro in human tubular cells and in vivo in
rat kidneys, and that autophagy serves as a protective
mechanism against cyclosporine toxicity.2 Importantly, we
demonstrated that cyclosporine-induced autophagy is trig-
gered by endoplasmic reticulum (ER) stress. ER stress occurs
when excessive amounts of misfolded proteins accumulate
inside the ER. Cells subjected to ER stress activate the
unfolded protein response to reduce the amount of
accumulated proteins. However, persistent ER stress may
lead to apoptosis. Recent evidence suggests that ER stress
drives autophagy3 and this self-digestion can rid cells of
superfluous or misfolded protein accumulation. Thus, it is
suggested that autophagy alleviates the deleterious effects of
ER stress by eliminating misfolded proteins. Cisplatin has
been shown to induce ER stress.4 It is therefore tempting to
speculate that autophagy induced by cisplatin is also due to
ER stress. As ER stress is an emerging pathological process in
kidney diseases,5 autophagy could constitute an adaptive
mechanism to kidney injuries far more common than
previously thought.
Thus, deciphering new biological pathways that induce
autophagy in kidney diseases is of great importance because
they may lead to the development of early biomarkers of
kidney injury and to new therapeutic options.
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We thank Dr. Pallet and Dr. Anglicheau for their interest in
our recent publication reporting autophagy in cisplatin
nephrotoxicity and its cytoprotective role.1 We are pleased
to learn that their latest work has also demonstrated
autophagy as a protective mechanism against cyclosporine
toxicity in renal cells and tissues.2 Interestingly, whereas
we showed the regulation of cisplatin-induced autophagy
by p53, BcL-2, and related mechanisms, Pallet et al. further
emphasized the involvement of ER stress in autophagy
during cyclosporine toxicity. Although we did not examine
ER stress in the cisplatin model, we believe this is a
possibility that deserves consideration and further inves-
tigation. As correctly pointed out, cisplatin can induce ER
stress. In this regard, Liu and Baliga3 showed evidence for
ER stress during cisplatin treatment of renal tubular cells.
Nevertheless, multiple stresses and signaling pathways are
induced or activated during cisplatin nephrotoxicity.4
Notably, cisplatin induces pathological alterations in
several subcellular sites or organelles including mitochon-
dria, ER, and the nucleus. As a result, cellular responses,
either cytoprotective or injurious, may be mediated by
multiple rather than a single mechanism.4 Certainly, a
specific stress or pathway may have a major role in the
induction of autophagy; whether it is ER stress remains to
be determined. In addition, the signaling pathways
activated by cisplatin may also cross talk and be integrated,
resulting in an impressive renal pathology. The recent
studies by this and other laboratories have suggested that
autophagy is a renoprotective mechanism during cisplatin
and cyclosporine nephrotoxicity.1,2,5 However, whether
this conclusion can be generalized to other kidney injury
models (for example renal ischemia-reperfusion) remains
to be investigated, as excessive autophagy can lead to cell
death. Thus we have to agree with Dr. Lieberthal that ‘the
extent to which autophagy can ameliorate kidney injury
caused by other types of renal insults remains to be
determined’.6 It is hoped that these studies have provided
impetus for investigation of autophagy in renal patho-
physiology.
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Telmisartan is more effective than
losartan in reducing proteinuria
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To the Editor: We read with interest the paper that
Telmisartan is more effective than losartan in reducing
proteinuria in patients with Diabetic Nephropathy recently
published in Kidney International by Bakris et al.1 where the
effects of telmisartan 80 mg was compared with losartan
100 mg in 860 patients with type 2 diabetes treated for 52
weeks. The authors showed that with telmisartan, proteinuria
decreased from 1.42 to 0.95 g per g creatinine (Po0.0001)
and with losartan, proteinuria decreased from 1.39 to 1.05 g
per g creatinine (Po0.0001) at the end of the study. They
also documented a trend in favor of telmisartan where there
was a difference of 4.2 mm Hg difference in systolic blood
pressure compared to losartan. We would like to comment on
the dose of telmisartan and losartan used in Bakri’s study.
From our observation, comparing telmisartan 80 mg with
losartan 100 mg would favor telmisartan with regards to
clinical efficacy in particular with respect to reduction of
proteinuria.
We would like to share our own experience in a clinical
trial involving patients with IgA nephritis treated with
losartan 100 mg (n¼ 45) compared to those treated with
losartan 200 mg (n¼ 61) over a 6-year period from 2001 to
2007.2 In the losartan 100 mg group, proteinuria decreased
from 2.1±1.0 to 1.7±1.0 g/day compared to losartan 200 mg
group where proteinuria decreased from 2.1±0.8 to
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